On November 12, 2024 Crescent Biopharma, Inc. ("Crescent"), a private biotechnology company dedicated to advancing novel precision engineered molecules targeting validated biology to advance care for patients with solid tumors, reported management will present at the JeCeries London Healthcare Conference on November 19, 2024, at 12:30 pm GMT/7:30 am EDT (Press release, Crescent Biopharma, NOV 12, 2024, View Source [SID1234648709]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available at wsw.com/webcast/jeC315/cresc/1987776. An archived recording will be available for 90 days following the event.

In late October, Crescent entered into an acquisition agreement with Rockville, Marylandbased GlycoMimetics, Inc. (NASDAQ: GLYC). Following closing, the combined company will operate under the name Crescent and advance its portfolio of precision-engineered biologics to improve outcomes for patients with solid tumors.